Ocular inflammation and dry eye.

Markers of infllammation expression in conjunctival epithelial cells of dry eye patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26452

Enrollment

Registered

2010-04-15

Start date

2010-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dry eye syndrome

Interventions

Treatment with Loteprednolol etabonate bid (bis in die = 2 times/day) for 14 days, once a day for 14 days and twice a week for 28 days will be given at the study group (N=10). The control group (N=10

Eligibility

Inclusion criteria

Inclusion criteria: 1. Symptoms of dry eye; 2. HLA-DR>15%; 3. And at least 2 of the following: A. Schirmer test 3.

Exclusion criteria

Exclusion criteria: 1. Glaucoma; 2. Ocular surface infections; 3. Corneal ulcer; 4. Conjunctival infections; 5. Treatment with anti-inflammatory drugs in the 3 months preceding the study; 6. Surgical procedures in the 3 months preceding the study; 7. Antiglaucoma therapies; 8. Contact lens use 7 days before the study.

Design outcomes

Primary

Measure	Time frame
Reduced level of expression of HLA-DR after treatment with Loteprednolol etabonate measured by flow cytometry.	—

Secondary

Measure	Time frame
Reduced symptoms (measured by means of a specific questionnaire, ocular surface disease index), and ocular surface signs (measured by fluorescin and lissamine green staining of the ocular surface) after treatment of dry eye.	—

Contacts

Public ContactStefano Barabino

Viale Benedetto XV, 5

barabino@schepens.harvard.edu+39 010 35338294

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)